Servier, Pierre Fabre and Sanofi acquire a new collection of PDX models

Discover and Share the Newsletter IMODI #2 – November 2016
Discover and Share the Newsletter IMODI #2 – November 2016
14/11/2016
Discover and Share the Newsletter IMODI #3 – March 2017
20/03/2017

Servier, Pierre Fabre and Sanofi acquire a new collection of PDX models

Servier, Pierre Fabre and Sanofi acquire a new collection of PDX models - IMODI Cancer

Servier, Pierre Fabre and Sanofi acquire a new collection of patient-derived xenograft (PDX) models for their translational breast cancer research.


This new collection represents 40 established breast PDX models reflecting the 4 major molecular clinical subtypes among which 37% are triple negative, 33% are Luminal B HER2 -, 22% are Luminal B HER2+ and 8% HER2+.

All PDX models are well-characterized and annotated under harmonized procedures by the IMODI consortium.




This collection of very well characterized models of human breast tumours obtained using high standards provides Servier Oncology with a powerful tool that can help to reveal the potential of the compounds in the field of immunotherapy and apoptosis which are two of our main areas of research.
said Alain Bruno, senior project leader, Translational and Clinical Research Oncology at Servier



The collection will be presented at the next AACR Congress with an oral presentation (Tuesday Apr 4, 2017 3:00 PM)




Get connected!

IMODI is now present on the Twitter and LinkedIn networks.
Follow us on @IMODI_Cancer and www.linkedin.com/company/imodi-cancer


Share this